Tumor necrosis factor-α (TNF-α)-induced RIP1/RIP3 (receptor-interacting protein kinase 1/receptor-interacting protein kinase 3)-mediated necroptosis has been proposed as an alternative strategy for treating apoptosis-resistant leukemia. However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/ RIP3/MLKL signaling, yet do not undergo necroptosis. TNF, through RIP1/RIP3 signaling, prevents degradation of SOCS1, a key negative regulator of interferon-γ (IFN-γ) signaling. Using both pharmacologic and genetic assays, we show here that inactivation of RIP1/RIP3 resulted in reduction of SOCS1 protein levels and partial differentiation of AML cells. AML cells with inactivated RIP1/RIP3 signaling show increased sensitivity to IFN-γ-induced differentiation. RIP1/RIP3 inactivation combined with IFN-γ treatment significantly attenuated the clonogenic capacity of both primary AML cells and AML cell lines. This combination treatment also compromised the leukemogenic ability of murine AML cells in vivo. Our studies suggest that inhibition of RIP1/RIP3-mediated necroptotic signaling might be a novel strategy for the treatment of AML when combined with other differentiation inducers.
INTRODUCTION
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy which shows increased incidence with advanced age. Currently, the 5-year overall survival is 40-45% for patients o 60 years of age and o 10% for patients aged ⩾ 60 years. [1] [2] [3] [4] Thus, the development of novel treatments for AML with minimal toxicity is urgent. The remarkable success of all-trans retinoic acid in combination with arsenic trioxide in the treatment of acute promyelocytic leukemia 5, 6 encourages us to search for novel differentiation-inducing therapies in the management of nonacute promyelocytic leukemia subtypes of AML.
In addition to stimulating nuclear factor-κB-mediated survival signaling, [7] [8] [9] tumor necrosis factor-α (TNF) also induces caspase-8-mediated apoptosis and RIP1/RIP3/MLKL (receptor-interacting protein kinase 1/receptor-interacting protein kinase 3/mixedlineage kinase domain-like)-mediated necroptosis, two mutually interconvertible programmed cell death signaling pathways. [10] [11] [12] [13] [14] Inactivation of the apoptotic pathway in the development of leukemia and the progression to drug resistance has been extensively studied. [15] [16] [17] However, the role of necroptosis in the pathogenesis of AML has not been significantly evaluated. [18] [19] [20] The normal phenotype of RIP3 −/− mice suggested that necroptotic signaling is not necessary for development and tissue regeneration during homeostatic conditions, 21 suggesting that inhibition of RIP1/RIP3 signaling would be safe.
We found that leukemic cells isolated from many AML patients express TNF, RIP1 and RIP3. Activation of RIP1/RIP3 signaling can be readily detected in AML cells and is required for maintaining the undifferentiated state of such malignant cells. Genetic or pharmacologic inactivation of the RIP1/RIP3 signal induces spontaneous differentiation and represses leukemogenic capacity of AML cells. RIP1/RIP3 signaling-inactivated AML cells are highly sensitive to interferon-γ (IFN-γ)-induced differentiation. Our studies suggest that inhibiting necroptotic signaling may be a new strategy to treat AML when combined with IFN-γ or other differentiation inducers.
MATERIALS AND METHODS

Ex vivo and in vivo transplantation and leukemogenesis
For ex vivo study, WT MA9-AML cells were treated with IFN-γ and Nec1 individually or in combination, whereas TNFR −/− , RIP1
−/− and RIP3 −/− MA9-AML cells were treated with IFN-γ only (1 ng/ml) for 5 days. The resultant cells were used for transplantation. AML cells with or without pretreatment were transplanted into lethally-irradiated recipient mice (2-month-old males) by tail vein injection. Each mouse received 5000 viable AML cells together with 2 × 10 5 support bone marrow (BM) cells. For in vivo treatment studies, WT, TNFR −/− intraperitoneal injection) or vehicle daily for 2 weeks. All mice were monitored for leukemia development by observing for symptoms such as hunched body, significant weight loss or hind-limb paralysis. The death of mice from leukemia was confirmed by examining white blood cell count and leukemic blasts in peripheral blood and infiltration of AML cells into spleens, livers and kidneys. The survival of recipient mice was monitored over time and analyzed by Kaplan-Meier survival graphing.
Competitive transplantation assay
To evaluate the reconstitutive capacity of BM cells following IFN-γ treatment, 2 × 10 6 BM mononuclear cells isolated from CD45.1 mice were treated with Nec1 (30 μM) for 48 h and then mixed with 2 × 10 6 freshly isolated BM mononuclear cells from CD45.2 mice. These cells were equally transplanted into lethally-irradiated CD45.2 mice. Peripheral blood samples were collected 3 months after transplantation and analyzed for the ratio of CD45.1 to CD45.2 in total mononuclear cell counts.
Microarray data analysis
We selectively analyzed the expression of the key components of the TNF, interleukin-1 (IL-1) and Toll-like receptor (TLR) signaling pathways in a cohort of 562 AML patients using a microarray data set GSE37642 (ref.22) (see Supplementary Table S1 , Supplementary Information, for details of the genes). The samples that showed similar patterns of expression of these genes were clustered together.
Statistical analysis
Data are expressed as mean ± s.d. One-way analysis of variance (multiple groups) and Student's t-test (two groups) were performed to determine the statistical significance of differences among and between experimental groups at Po0.05. The number of mice used in the experiments was determined by two-tailed analysis of variance analysis to obtain 485% power.
Cytokine profile analysis
WT, RIP1
−/− and RIP3 −/− AML cells (2 × 10 5 /ml) were cultured in 4-cytokine medium for 24 h. Supernatants were collected for cytokine profile analysis by Bio-Plex Pro mouse cytokine 23-Plex Assay (Bio-Rad, Hercules, CA, USA; M60-009RDPD) following the vender's instructions.
RESULTS
Basal activation of RIP1/RIP3 signaling in human AML cells Our analysis of a large-scale AML patient cohort (N = 562, GSE37642 cohort) showed that the expression of many key components of inflammatory signaling pathways (Supplementary  Table S1 ), such as TNF, tumor necrosis factor receptors (TNFRs), TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor, IL-1α/β, TLRs and MYD88, were greatly elevated in leukemic cells isolated from M4 and M5 subsets of AML patients (Figure 1a) . We also noticed that the key necroptotic mediator, RIP3 kinase, was greatly elevated in these samples (Figure 1a) . Consistent with previous reports, [23] [24] [25] [26] we found that necroptosis can be readily induced using TNF+Smac-mimetics+a caspase inhibitor in AML cells, which results in extensive cell death within 20 h in in vitro culture, suggesting that the Rip3-Mlkl-mediated necroptotic signaling pathway is intact in AML cells (Supplementary Figure S1) .
Necroptotic signaling is primarily stimulated by TNF in most types of cells. We have reported that most AML cells produce TNF that stimulates the growth of AML cells in an autocrine manner. 27 To study whether some degree of activation of necroptotic signaling is present in AML cells, we examined the expression and activity of RIP1/RIP3 signaling by measuring the levels of RIP1 and RIP3 proteins as well as the phosphorylation of RIP1, RIP3 and MLKL (key downstream mediator of RIP1/RIP3 activation) in human AML cell lines including ML-2 (M4), Molm13 (M5a), U937 (M5), THP1 (M5a), MM6 (M5), HL-60 (M2) and NB4 (M3), as well as K562, a Bcr-Abl-expressing erythroid leukemia cell line derived from chronic myeloid leukemia. ML-2, Molm13, U937, THP1 and MM6 are mixed lineage leukemia (MLL)-rearranged AML cells. Phosphorylated forms of RIP1 (p-RIP1-Ser166), RIP3 (p-RIP3-Ser227) and MLKL (p-MLKL Thr357/Ser358) were present in all AML cell lines tested but were barely detectable in healthy CD34 + hematopoietic stem/progenitor cells (HSPCs; Figure 1b) . Although most other cell lines express one isoform of RIP1 and RIP3, two splicing isoforms of RIP1 and RIP3 were detected in U937, THP1 
TBZ treated ML2 cells and HL60 cells that correlated to reduced expression of both RIP1 and RIP3 (Figure 1b) . Immunofluorescence assays demonstrated that, in contrast to necroptosis induced by TNF-α plus birinapant and Z-VAD treatment, in which p-MLKL protein is aggregated within the cytoplasm and cell membrane, in AML cells, basal level p-MLKL is localized to the nucleus and stains strongly on the centrosome/spindle of dividing cells (Figure 2b ). In addition, we examined the expression and activation of RIP1 and RIP3 in primary leukemia samples. As shown in Figure 1c , expression of p-RIP1, RIP1, p-RIP3 and RIP3 was detected in all AML patient samples but not in healthy donor samples. Myeloproliferative neoplasm samples showed lower levels of RIP3 and p-RIP3 when compared with AML samples. RIP3 and p-RIP3 levels appeared to positively correlate to the percentage of leukemic blasts. These data suggested that a basal level activation of the RIP1/RIP3/MLKL pathway exists in AML cells when grown under standard culture conditions without any stimulation. RIP1/RIP3 inhibition sensitizes human AML cells to IFN-γ-induced differentiation To study the roles of basal level activation of RIP1/RIP3 signaling in AML cells, we examined cell growth, morphology and clonogenic ability in a variety of AML cell lines after blocking RIP1/RIP3 interaction using Necrostatin 1 (Nec1), the best-characterized necroptotic inhibitor. 28, 29 We and others determined that 20-30 μM of Nec1 can largely prevent TNF-induced necroptosis in most types of cells. 30, 31 We also determined that Nec1 has negligible influence on healthy HSPCs when its concentration is o150 μM. 30 Therefore, we used 30-50 μM Nec1 to treat AML cells in the current study. We found that the reduced growth, proliferation and survival of AML cells could only be observed 4 days after Nec1 treatment (Figure 2a and Supplementary Figure S2) . Consistently, Nec1 treatment inhibited the clonogenic ability of AML cells in almost all examined AML lines to some extent (Supplementary Figure S3) . We believed that the growthinhibitory effect of Nec1 on AML cells was due to differentiation, as demonstrated by mature monocyte/macrophage morphology (Supplementary Figure S4a) and increased expression of the differentiation markers CD11B and CD14 (Supplementary Figure S4b) .
Consistent with previous studies, IFN-γ inhibits growth by inducing the differentiation of AML cells [32] [33] [34] (Supplementary Figure S4) . The partially differentiated morphology of AML cells after Nec1 treatment encouraged us to test whether Nec1 treatment combined with IFN-γ could induce a more complete differentiation in AML cells. As expected, combination treatment of Nec1 with IFN-γ further promoted differentiation and repressed RIP1/RIP3 knockout attenuates leukemogenic capacity To more specifically understand the role of necroptotic signaling in the pathogenesis of AML, we examined the effects of genetic inactivation of RIP1 and RIP3 on AML development and progression using a murine Mll-AF9 (MA9)-AML model (M5 subtype). We found that mice receiving MA9-transduced RIP1 −/− (RIP1 knockout) or RIP3 −/− (RIP3 knockout) HSPCs showed a significantly longer latency to AML development than mice receiving MA9-transduced WT (wild-type) HSPCs. Significantly delayed leukemia development and reduced leukemia-related mortality were also observed in mice receiving RIP1 −/− and RIP3 −/− AML cells upon secondary transplantation (Figure 3a ). RIP1 and RIP3 knockout in AML cells was verified by western blotting (Supplementary Figure S6a) . To study the mechanism by which inactivation of RIP1/RIP3 signaling influences AML development, we compared the cell cycle, proliferation, survival and differentiation of WT, RIP1
−/− and RIP3 −/− AML cells. We found that proliferation was reduced in Figure S9) , suggesting that Nec1 had a reasonable specificity in terms of blocking RIP1/RIP3 signaling. To evaluate whether inactivation of the RIP1/RIP3 signal synergizes with IFN-γ to repress the colony-forming ability of AML cells, WT AML cells were treated with Nec1 and IFN-γ individually or in combination, whereas RIP1 −/− or RIP3 −/− AML cells treated with 1 ng/ml IFN-γ were seeded into methylcellulose for colonyforming unit assay. As shown in Figure 4b , after inactivation of the RIP1/RIP3 signal by Nec1 treatment or genetic deletion, IFN-γ treatment results in a remarkably reduced number of colonies.
To evaluate whether the differentiation induced by combining IFN-γ with inactivation of RIP1/RIP3 signaling was capable of reducing the leukemogenic capability of MA9-AML cells, an index of reduction of leukemogenic capability, we treated WT AML cells with Nec1 (30 μM) and IFN-γ (1 ng/ml) individually or in combination and RIP1
−/− and RIP3 −/− MA9 AML cells with IFN-γ (1 ng/ml) alone for 5 days. We subsequently collected live cells for transplantation and leukemogenic analysis. As indicated in Supplementary Figure S10 , whereas all recipient mice receiving Nec1-treated WT MA9-AML cells and most recipients receiving IFN-γ treated WT MA9-AML cells died 25-50 days post transplantation, recipient mice that received WT AML cells treated with a combination of IFN-γ and Nec1 showed increased latency to leukemia (∼50 days) and reduced mortality, with 40% mice remaining alive and leukemia-free for up to 120 days. In contrast, mice receiving RIP1 −/− and RIP3 −/− MA9-AML cells treated with IFN-γ did not develop leukemia for up to 120 days. These data suggested that RIP1/RIP3 inactivation plus IFN-γ-induced differentiation results in a reduction of leukemogenic capability.
To evaluate the efficacy of IFN-γ treatment in vivo, we transplanted WT, RIP1
−/− and RIP3 −/− MA9-AML cells into lethally-irradiated recipient mice along with supporting BM cells. Starting 15 days following transplantation, recipient mice were given IFN-γ (2.5 μg/mouse) daily for 2 weeks. Although IFN-γ showed very limited effects in inhibiting leukemogenesis in WT AML cells, it significantly delayed leukemia development and reduced mortality in RIP1 −/− and RIP3 −/− MA9 AML cells (Figure 4c ). These data suggest that the RIP1/RIP3 pathway is a promising target for anti-AML therapy.
TNFR knockout sensitizes AML cells to differentiation in vitro but not in vivo Because (1) AML cells produce TNF (Supplementary Table S2 and Supplementary Figure S6b) , (2) necroptosis is primarily induced by TNF in AML cells and (3) TNF inhibitors have been used clinically, we examined whether TNF is the key stimulator of RIP1/RIP3 signaling in AML and evaluated the potential application of this for anti-TNF therapy. We found that although the morphology, CD117 + CD11b low population percentage and clonogenic ability (Supplementary Figures S11a-c Figure S8) . The growth of WT AML cells was inhibited by IFN-γ in a dosedependent manner (Supplementary Figure S8) ; even 10 ng/ml of IFN-γ failed to completely repress the growth of WT AML cells. In contrast, the growth inhibition of TNFR −/− AML cells was observed at as low as 0.1 ng/ml of IFN-γ, and complete inhibition was achieved at 0.5 ng/ml (Supplementary Figure S11) . By day 5 of treatment, TNFR −/− AML cells showed massive death and the remaining viable cells showed terminally differentiated morphology ( Supplementary Figures S8 and 11) . IFN-γ treatment also reduced the clonogenic capability of TNFR −/− AML cells in vitro (Supplementary Figures S11d-f) . However, ex vivo, but not in vivo, IFN-γ treatment delayed AML development in both WT and Figure S11g and h) . We speculate that RIP1/RIP3 signaling is primarily activated by TNF in in vitro culture, but can also be activated by other inflammatory factors in vivo, including TLR, TRAIL and IL-1β. Induced cell differentiation was followed by apoptosis In normal tissue cells, RIP1 prevents IFN-γ-induced RIP3-medicated necroptosis in a kinase activity-independent manner. 13, 36, 37 Interestingly, we found that RIP3 levels were dramatically decreased in RIP1 −/− AML cells (Supplementary Figure S6) Figure 5c ). We speculated that caspase activation and apoptosis are secondary events in differentiation, which explains why AML cells become short-lived following the induction of differentiation. This was supported by our data showing that the inhibition of caspase activity later on in treatment slightly increased cell counts (Supplementary Figure S12c) and delayed cell death (Supplementary Figure S12d) , but failed to block differentiation (Supplementary Figure S12e) . Such a phenomenon was also detected in several human AML cell lines. In these cell lines, we found that Nec1 and IFN-γ-induced AML cell differentiation was followed by cell cycle arrest and activation of caspases (Supplementary Figure S13) , indicating an induced normal maturation process in these malignant cells.
IFN-γ and Nec1 show minimal inhibition of normal HSPCs
One concern for the use of IFN-γ and RIP1 inhibitors to treat AML is their potentially repressive effects on normal HSPCs. Therefore, we examined the influence of Nec1 and IFN-γ treatment on the survival and colony-forming ability of BM HSPCs. We found that Nec1 was toxic and had inhibitory effects on colony formation of WT HSPCs when its concentration was 4200 μM (Supplementary Figures S14a and b) , in contrast to 10 μM for MA9-AML cells (Supplementary Figure S14c) . IFN-γ appears to have minimal effects on the clonogenic ability of BM HSPCs even at a concentration of 10 ng/ml, regardless of the intact state (WT) or inactivated state (TNFR −/− or RIP3 −/− ) of TNFR/RIP3 signaling ( Supplementary Figures S14d and e) . In contrast, the effective dose of IFN-γ was 0.1 ng/ml for TNFR −/− and RIP3 −/− AML cells (Figure 4 and Supplementary Figure S11 ). In addition, we found that doses of 100 μM Nec1 and 1 ng/ml IFN-γ have no significant effects on the reconstitutive capacity of normal HSPCs (Supplementary Figures S15f and g ). Such a dose-response difference between AML cells and HSPCs to IFN-γ and Nec1 provides us with a valuable window for these agents to be used to specifically treat leukemia with a negligible deleterious influence on normal hematopoiesis.
RIP1/RIP3 inhibition sensitizes primary AML cells to differentiation
Consistent with what was observed in murine HSPCs, neither Nec1 nor IFN-γ, individually or in combination, had a negative impact on the differentiation and colony formation of normal human CD34 + HSPCs (Figures 6a and b) . To study the efficacy of Nec1 and IFN-γ treatment on human primary AML samples, we examined the responses of 10 human primary leukemic cell samples (5 newly diagnosed cases: 1 M0, 2 M1 and 2 M5; and 4 cases secondary to myelodysplastic syndrome, 1 case secondary to therapy, see Supplementary Table S2 in Supplementary Information) to Nec1 and IFN-γ treatment. Colony growth was achieved in seven samples, whereas three samples from patients with AML secondary to myelodysplastic syndrome failed to grow colonies. Among these seven colony-growing samples, Nec1 and IFN-γ treatment had at least an additive effect on all of them in terms of repression of clonogenic capacity regardless of their disease subtype ( Figure 6 and Supplementary Table S2) . Following treatment, AML cells isolated from all seven responsive samples underwent differentiation, as demonstrated by morphologic analysis (Figure 6a ) and increased expression of the differentiation markers CD11b (Figure 6c ) and CD14 (Supplementary Figure S15a) , as well as by reduced size and number of colonies (Figures 6a and b) . Significant cell cycle arrest following Nec1 and IFN-γ treatment was observed after 5 days of treatment, in accordance with the time when the cells showed a pronounced differentiated morphology (Supplementary Figure S15b) . Among these seven AML samples, two have MLL-fusion genes, four samples have NPM mutations, whereas one has DNMT3a mutation. These results suggested that RIP1/RIP3 inhibition combined with IFN-γ might be a good treatment option for treatment of AML cases in humans showing these genomic abnormalities (Supplementary Table S2 ).
TNF-RIP1/RIP3 signaling maintains SOCS1 levels To understand the underlying mechanism by which inactivation of the TNFR/RIP1/RIP3 pathway facilitates IFN-γ-induced leukemic cell differentiation, we first examined the influence of TNFR/RIP1/RIP3 signaling inactivation on IFN-γ signaling transduction using murine MA9-AML cells. Despite lower levels of total signal transducer and activator of transcription 1 (STAT1) expression in Figure S19) . Altogether, these data establish the functional role of TNFR/RIP1/RIP3 signaling in the maintenance of the lack of differentiation in AML cells. This effect is partially mediated by the repression of IFN-γ/STAT1 signaling that maintains SOCS1 levels.
DISCUSSION
Chemical-induced necroptosis has been investigated as a means of treating drug-resistant cancers. 25, [38] [39] [40] Its value is still controversial because of several concerns. First, although short-term reductions of tumor size have been observed in certain types of cancer, any long-term benefits associated with such treatment appear to be limited. [41] [42] [43] Second, spontaneous necroptosis has been observed in some solid tumors but is associated with poor prognosis. [44] [45] [46] Third, necroptosis is involved in many clinical disorders such as myocardial infarction and stroke, atherosclerosis, ischemia-reperfusion injury, pancreatitis and inflammatory bowel diseases. 13, 14, 19 Finally, necroptotic cells release molecules that + cells purified from two healthy donors' peripheral blood and primary AML cells isolated from 7 AML patients were seeded for colony-forming unit (CFU) assay (40 000 cells/dish, in triplicate) in the presence of dimethyl sulfoxide (DMSO), Nec1 (50 μM), hIFN-γ (5 ng/ml) or IFN-γ+Nec1 (I+N), respectively. After culturing for 9 days, colonies and cell morphologies were examined and photographed (a) and total numbers of CFUs were counted and compared (b). *P o 0.05, compared with vehicle control, # P o 0.05, compared with IFN-γ group; scale bar = 15 μm. Relative CFU was normalized to DMSO group. Absolute CFU numbers are shown in Supplementary Table S2 . (c) AML cells were cultured in liquid medium and treated with Nec1 and IFN-γ individually or in combination. Differentiation was evaluated by fluorescence-activated cell sorting (FACS) for CD11b on day 2 (D2) and day 5 (D5). Data in (a) and (c) are representative of one of two healthy donors and one of the seven colony-forming AML samples.
induce systemic inflammatory reactions 13, 14, 19 and may stimulate tumor cell growth. 47, 48 Therefore, induced necroptosis as a treatment for cancer might not appear to be an ideal strategy. To that end, our current studies indicate that the inhibition of necroptotic signaling may benefit certain AML patients and should be safe, without the induction of deleterious side effects. In addition, although our array data showed that the components of inflammatory signaling and RIP3 are more highly expressed in M4 and M5 subtypes of AML, the synergistic repressive effects of Nec1 plus IFN-γ were observed in all of the primary AML samples we studied regardless of their subtype, suggesting that such treatment might not limited to monocytic leukemia. While this paper was under revision, a report by Hockendorf et al. 49 demonstrated that TNF/RIP3 signaling restricts FLT3 internal tandem duplication and RUNX-ETO-induced AML development by repressing IL-1-induced differentiation and MLKL-mediated cell death. We previously reported that TNF stimulates the growth of MLL-AF9 AML cells but represses the growth of RUNX-ETO AML cells. Thus, we speculate that the role of RIP3 signaling in AML pathogenesis might be cell context dependent, determined by the leukemic driver genes. The AML patient samples in our study contain MLL-fusion genes, NPM1 or DNMT3a mutations. We did not find FLT3 internal tandem duplication and RUNX-ETO in our patient samples. However, a large number of patient samples need to be tested in order to determine the correlation of patient genetic abnormalities to the responses to Nec1 and IFN-γ treatment.
The inhibition of RIP1 −/− and RIP3 −/− AML by IFN injection in vivo suggested that the combination of a necroptosis inhibitor plus IFN might be an effective treatment for AML patients. Inactivation of TNF signaling in AML cells can reproduce the RIP1 −/− and RIP3 −/− AML phenotype in in vitro culture. However, the reduced sensitivity of TNFR −/− AML cells to IFN-γ treatment in vivo suggests that anti-TNF may be insufficient to fully block RIP1/RIP3 signaling in vivo because of other stimulating agents, 50 and that directly targeting RIP1/RIP3 is necessary. Unfortunately, because of the short life of Nec1 in vivo, we were unable to show the effects of pharmacologic inhibition of necroptosis on AML development in vivo. We intend to test optimized, stable necroptotic inhibitors such as Nec1-stable 51 to further evaluate the translational potential of our study results. Although we currently do not know whether RIP1 −/− and RIP3 −/− AML cells are more sensitive to the toxicity of the immune response, we found that RIP1 −/− and RIP3 −/− AML cells are highly sensitive to IFN-γ-induced differentiation in vitro. We believe that a RIP1/RIP3 inhibitor will be an effective treatment for AML when combined with specific chimeric antigen receptor T cells (that express high levels of IFN-γ) by inducing AML cell differentiation.
Because the leukemogenic capacity of RIP1 −/− AML cells was much more compromised than it was in RIP3 −/− AML cells, we speculate that other signaling pathway(s) downstream of RIP1 and parallel to the RIP3 pathway might also be involved in AML development. Several recent studies suggest that the scaffolding activity of RIP1 plays an essential role in maintaining tissue homeostasis by preventing TNF-induced apoptosis and IFN-γ or TLR signaling-stimulated necroptosis in skin, intestine and hematopoietic tissues. 10, 11, [52] [53] [54] Further studies are needed to elucidate the role of TNF and the scaffolding activity of RIP1 in the pathogenesis of AML. In addition, the scaffolding activity of RIP3 is required for caspase 8-mediated apoptosis. 55, 56 It will be interesting to determine whether RIP3 kinase inhibitors are more effective than RIP1 inhibitors in eliminating AML cells when combined with IFN-γ. 
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